Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?

Rajshekhar Chakraborty, Navneet S. Majhail, Faiz - Anwer

Research output: Contribution to journal › Comment/debate

2 Scopus citations

@article{c9f7001e312043ccb3d9f97c149048e7,

title = "Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?",

author = "Rajshekhar Chakraborty and Majhail, {Navneet S.} and Anwer, {Faiz -}",

year = "2019",

month = jan

day = "1",

doi = "10.1001/jamaoncol.2019.1598",

language = "English (US)",

journal = "JAMA oncology",

issn = "2374-2437",

publisher = "American Medical Association",

}

TY - JOUR

T1 - Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma

T2 - What Are the Unanswered Questions?

AU - Chakraborty, Rajshekhar

AU - Majhail, Navneet S.

AU - Anwer, Faiz -

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85068319727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068319727&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.1598

DO - 10.1001/jamaoncol.2019.1598

M3 - Comment/debate

AN - SCOPUS:85068319727

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -